Table 3.
Absolute values (and standard deviations) for Cramér-Rao Lower Bound estimates for each metabolite in each voxel
| Voxel | Drug | Metabolite | TD | ASD | N (TD, ASD) | F(dof) | p-value |
|---|---|---|---|---|---|---|---|
| BG | PLC | GABA+ | 4.56 (0.66) | 4.82 (0.81) | 17, 17 | F(1) = 1.095 | p = 0.303 |
| Glx | 7.50 (2.09) | 7.56 (2.25) | 17, 16 | F(1) = 0.007 | p = 0.935 | ||
| CBD | GABA+ | 4.59 (0.62) | 4.25 (1.43) | 17, 16 | F(1) = 0.782 | p = 0.383 | |
| Glx | 7.82 (3.00) | 6.75 (2.48) | 17, 16 | F(1) = 1.236 | p = 0.275 | ||
| DMPFC | PLC | GABA+ | 6.47 (0.87) | 7.38 (2.06) | 17, 16 | F(1) = 2.751 | p = 0.107 |
| Glx | 5.68 (0.73) | 5.88 (1.02) | 17, 16 | F(1) = 0.416 | p = 0.524 | ||
| CBD | GABA+ | 6.29 (0.85) | 7.69 (2.69) | 17, 13 | F(1) = 4.102 | p = 0.052 | |
| Glx | 6.24 (1.95) | 6.31 (1.55) | 17, 13 | F(1) = 0.12 | p = 0.913 |
ASD autism spectrum disorder, BG basal ganglia, CBD cannabidiol, DMPFC dorsomedial prefrontal cortex, F(dof) F statistic and degrees of freedom, GABA + g-aminobutyric acid + macromolecule, Glx glutamate + glutamine, N number of individuals, PLC placebo, TD typically developing individuals